Adagrasiib drug introduction

Adagrasib is a new type of targeted therapy drug that is a KRAS G12C inhibitor. It is an innovative drug specifically targeting advanced or metastatic non-small cell lung cancer (NSCLC) and other solid tumors with KRAS G12C mutations.

The KRAS G12C mutation is a common oncogenic mutation found in a variety of cancers. This mutation causes abnormal proliferation and growth of tumor cells, making tumors more difficult to treat. The development of adagrasib aims to target this mutation and inhibit the proliferation and growth of cancer cells by interfering with the activity of the KRAS G12C mutant.

Adagrasiib is taken orally, 600mg twice daily. Clinical trials have shown that adagrasib exhibits significant anti-tumor activity in some patients with advanced cancer. Although further research is still needed to determine its long-term efficacy and safety, adagrasib provides a new treatment option for patients with KRAS G12C mutated tumors and brings new hope to the field of cancer treatment.

However, adagrasib may also cause some side effects, such as fatigue, nausea, vomiting, rash, etc., so close monitoring and management are required during use. Before using adagrasib, patients should consult their doctor and fully understand the drug's usage, side effects, and precautions to ensure safe and effective treatment.

Adagorasib has not yet been introduced in China, so domestic patients cannot purchase it directly and can only turn to foreign markets. However, the price of original drugs in the United States is as high as 180,000 yuan, which is undoubtedly a heavy burden for ordinary families. The good news is that generic drugs of adagrasibu have recently been launched abroad, including products from Lucius Pharmaceuticals of Laos, which sell for only four to five thousand yuan per box, which is significantly lower than the price of the original drug. What’s even more gratifying is that this generic drug has basically the same ingredients as the original drug, providing patients with a more economical choice.